Novo Nordisk's Buyback and Hemophilia Pipeline Provide Twin Catalysts for Stock Recovery

Novo Nordisk shares rally 13% but remain 29% below peak. Ongoing buyback (44% of 15B kr goal) and positive Denecimig hemophilia A trial data support recovery. FDA decision awaited.

Investors in Novo Nordisk are watching two distinct narratives converge as the Danish pharma giant works to regain ground from a bruising 12-month stretch. Shares have rallied more than 13% over the past month, yet remain roughly 29% below the 52-week high of 60.95 euros set in July 2025. The stock closed at 43.15 euros on July 13, down 0.4% on the day, but two underlying forces are giving the recovery tangible support: a relentless share buyback programme and encouraging late-stage data from its hemophilia A pipeline.

The buyback, which has run without interruption since early February, reached a notable milestone last week. Between July 6 and July 10, Novo Nordisk purchased 195,000 B-shares daily at prices ranging from 320.62 to 327.75 Danish kroner each. That tranche brought the total number of B-shares bought back to 23,984,179 since February, representing an outlay of 6.53 billion Danish kroner at an average price of 272.45 kroner. With roughly seven months left on a 12-month programme targeting 15 billion kroner, the company has already completed about 44% of that goal.

The pace has been adjusted slightly in recent days. Earlier in July, daily purchases stood at 200,000 shares at similar price levels; the reduction to 195,000 is a modest trim. The current tranche operates under a framework announced on May 6, authorising up to 11.2 billion kroner in buybacks through February 1, 2027. Novo Nordisk now holds 41,169,480 treasury B-shares, equivalent to 0.9% of its total capital base of 4.465 billion A- and B-shares. The company says the programme serves to reduce share capital and to service equity-based compensation plans, for which up to 400 million B-shares are reserved.

Alongside the buyback, clinical data presented at the International Society on Thrombosis and Haemostasis congress in Paris are strengthening the case for Denecimig, an experimental antibody that mimics clotting factor VIIIa. Interim results from the FRONTIER4 phase 3 extension study showed that 71% of adults and adolescents, and 89% of children, experienced no bleeding episode requiring treatment under Denecimig prophylaxis. The open-label study enrolled 426 patients aged one year and older, both with and without inhibitors. Injection-site reactions were mild and transient, occurring in 2.0% of injections in children and 1.8% in adolescents and adults. No neutralising antibodies were detected.

The FDA submission for Denecimig was filed in September 2025, and the regulator's decision is awaited. Martin Holst Lange, Novo Nordisk's head of research, said the new data reinforce the drug's potential as a prevention option for a broad patient population. The company also released early results from the explorer10 phase 3 trial of Concizumab, an already approved therapy, in 24 children under 12 with haemophilia A or B and inhibitors. The annualised bleeding rate dropped 82% compared with previous on-demand treatment.

From a technical standpoint, the stock has work still to do. As of a recent session, the 50-day moving average stood at 39.62 euros and the 200-day average at 40.57 euros, levels the share price has now cleared by 9.2% and 6.6% respectively. The relative strength index of 65.5 signals that bullish momentum is building but the stock is not yet overbought. After hitting a 52-week low of 30.25 euros in March, the rebound of 42.6% to current levels is striking, but the share price still trades below several key moving averages on a longer timeframe.

Novo Nordisk has committed to weekly updates on the buyback's progress. With the February 2027 deadline still some way off, the programme appears on track to hit its full target. Whether the FDA decision on Denecimig can act as the next catalyst will become clearer in the coming months. For now, the combination of a steady share repurchase and advancing pipeline data is providing a foundation for the recovery — one that is still in its early innings.